Wednesday, July 8, 2026

Patent intelligence · US

US 7220719

Modulation of endogenous gene expression in cells

granted A61KA61K48/00A61K48/005A61P
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 1
Applicant portfolio 192
Patent details — US 7220719
Jurisdiction
US
Status
granted
Grant date
May 22, 2007
Expiration
May 17, 2027
Claims
25
CPC classes
A61K, A61K48/00, A61K48/005, A61P
View on Google Patents ↗

Quick answer

US 7220719 (Modulation of endogenous gene expression in cells) is held by Sangamo Biosciences, Inc.. Status: granted. Granted May 22, 2007. Expires May 17, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
25
CPC classes
A61K, A61K48/00, A61K48/005, A61P, A61P11/00, A61P17/06

More from Sangamo Biosciences, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12318427

    Methods and compositions for modulation of tau proteins

    Sangamo Therapeutics, Inc. · Expires May 29, 2045

    granted
  2. US 12139517

    Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof

    Sangamo Therapeutics, Inc. · Expires Nov 7, 2044

    granted
  3. US 12043650

    Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

    Sangamo Therapeutics, Inc. · Expires Jul 18, 2044

    granted
  4. US 11981967

    Engineering AAV

    Sangamo Therapeutics, Inc. · Expires May 9, 2044

    granted
  5. US 11981739

    Chimeric antigen receptor specific for interleukin-23 receptor

    SANGAMO THERAPEUTICS FRANCE · Expires May 9, 2044

    granted
  6. US 11920169

    Compositions for linking DNA-binding domains and cleavage domains

    Sangamo Therapeutics, Inc. · Expires Feb 29, 2044

    granted
  7. US 11898158

    Methods and compositions for the treatment of lysosomal storage diseases

    Sangamo Therapeutics, Inc. · Expires Feb 8, 2044

    granted
  8. US 11884930

    Method of inactivating a glucocorticoid receptor gene in an isolated cell

    Sangamo Biosciences, Inc. · Expires Jan 25, 2044

    granted

Frequently asked questions

What is US patent 7220719?

US 7220719 (Modulation of endogenous gene expression in cells) is held by Sangamo Biosciences, Inc.. Status: granted. Granted May 22, 2007. Expires May 17, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7220719?

Sangamo Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 192 pharmaceutical patents for this assignee.

When does US 7220719 expire?

Our index shows an expiration date of May 17, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.